Hostname: page-component-76d6cb85b7-2r2wp Total loading time: 0 Render date: 2026-07-20T05:22:16.361Z Has data issue: false hasContentIssue false
  • English
  • Français

Reviewer Comment on Kang et al. “Highly Purified Cannabidiol Treatment Outcomes in Pediatric Patients with Highly Refractory Epilepsy at a Tertiary Center”

Published online by Cambridge University Press:  31 March 2026

Puneet Jain Open the ORCID record for Puneet Jain [Opens in a new window]  and
Robyn Whitney
Puneet Jain*
Affiliation:
Epilepsy Program, Division of Neurology, Department of Pediatrics, Hospital for Sick Children (HSC), University of Toronto, Toronto, Ontario, Canada
Robyn Whitney
Affiliation:
Division of Neurology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
*
Corresponding author: Puneet Jain; Email: puneet.jain@sickkids.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Reviewer Comment
Information
Canadian Journal of Neurological Sciences , First View , pp. 1
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Whitney, R, Jauhari, P, Jain, P. Cannabinoid use in pediatric epilepsy. Indian Pediatr. 2025;62:300–5.CrossRefGoogle ScholarPubMed
Kang, KGR, Boelman, C, Connolly, M, Huh, L, Datta, A. Highly purified cannabidiol treatment outcomes in pediatric patients with highly refractory epilepsy at tertiary center. Can J Neurol Sci (In press). 2026;1–26. https://doi.org/10.1017/cjn.2026.10554.Google ScholarPubMed
Saranti, A, Dragoumi, P, Pavlogiannis, K, Pavlou, E, Zafeiriou, D. Efficacy and safety of cannabidiol in children with developmental and epileptic encephalopathies: a systematic review. Seizure. 2025;133:114–27.CrossRefGoogle ScholarPubMed
Chemaly, N, Kuchenbuch, M, Losito, E, et al. Assessing real world efficacy, safety, and 18-month retention rates of cannabidiol in individuals with drug resistant epilepsies. Eur J Neurol. 2025;32:e70304.CrossRefGoogle ScholarPubMed
Cohen, NT, Bahar, B, Conry, JA, Schreiber, JM. Variability in serum concentrations and clinical response in artisanal versus pharmaceutical cannabidiol treatment of pediatric pharmacoresistant epilepsy. J Pediatr Pharmacol Ther. 2022;27:558–63.Google ScholarPubMed
Samanta, D, Naik, S. Efficacy and safety of cenobamate in developmental and epileptic encephalopathies: a systematic review and meta-analysis. Seizure. 2026;134:86–96.CrossRefGoogle ScholarPubMed